Regarding PFS, multivariate analysis showed that high serum β2-microglobulin (p = 0.002), creatinine clearance <30 mL/min (p = 0.04), G3-4 anemia in any phase of treatment (p = 0.05), ISS (p = 0.01), frailty score (p = 0.03) and ECOG (p = 0.01) negatively impact on PFS, while G-CSF (p = 0.002) use, response deepness (p = 0.000), therapy delay (p = 0.01) and use of erythropoietin positively impact on PFS. This evidence concerns the gene CSF3 and anemia (phenotype).